Rapport Therapeutics (RAPP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Rapport Therapeutics

NasdaqGM•Healthcare•Biotechnology

$40.45-1.50(-0.04%)After hours

Market Cap

$1.92B

P/S

96.0x

P/B

4.5x

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

How this company scores

WeakMetricSide Score: 33/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (4/25).

Profitability4/25

Growth8/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 96.0x5y range 65.4x – 96.0x

P/B · 4.5x5y range 0.7x – 4.5x

Currently above its 9-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.92B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $20.00M
Q. Revenue: $0
TTM EBITDA: $-152.56M
TTM Op. Income: $-153.52M
Q. Op. Income: $-60.81M
TTM Net Income: $-137.16M
Q. Net Income: $-56.62M
EPS: $-1.19
Shares Out.: $47.47M

$20.00M in TTM revenue grew from zero YoY, reaching $0 last quarter. TTM EBITDA of $-152.56M and TTM operating income of $-153.52M show growth is flowing through to the bottom line. However, net income is negative at $137.16M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -6080600000.0%
Net Margin: -5661500000.0%

Op. margin of -6080600000.0% is down 3131000000.0% YoY — costs are rising relative to revenue. Net margin at -5661500000.0% Over the past year, operating margin is down 106% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 96.0x
P/B Ratio: 4.5x

P/S of 96.0x and P/B of 4.5x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $458.98M
Cash: $63.61M
Long-Term Debt: N/A
Book Value: $422.93M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-41.45M
TTM Free Cash Flow: $-97.15M
FCF Margin: -485.7%
FCF / Net Income: 0.7

TTM FCF of $-97.15M on $-41.45M in operating cash flow. The FCF / Net Income ratio of 0.7x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 26% — a weakening trend.